Novartis cleared by EC for a COPD treatment - MarketWatch
Links shared publicly online about this topic.
- 1,557total visits
Novartis cleared by EC for a COPD treatment - MarketWatch
TEL AVIV (MarketWatch) -- Novartis, the Basel drugmaker, said on Thursday that the European Commission approved Onbrez in 150- and 300-microgram doses as a once-daily bronchodilator treatment for airflow obstruction in adults who suffer from chronic obstructive pulmonary disease. The product contains the active ingredient indacaterol maleate, Novartis said. COPD, which impairs lung function and causes chronic breathlessness, affects 210 million people worldwide and as many as 82 million of them
View full resource at marketwatch.com
Tags: Lung, COPD, Disease and Condition, Novartis, Pulmonology
Most Recently Shared on December 3, 2009 at 4:09 pm By:
Novartis cleared by EC for a COPD treatment http://is.gd/5bfub
Novartis receives approval in the European Union for Onbrez Breezhaler, a new once-daily bronchodilator for patients with COPD
novartis.com — “Basel, December 3, 2009 - Novartis announced today that the European Commission (EC) has approved Onbrez Breezhaler (QAB149 or indacaterol) in both 150 mcg and 300 mcg doses as a new once-daily maintenance bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease (COPD).” View full resource at novartis.com
Most Recently Shared on December 3, 2009 at 1:40 pm By:
eyeonfda Pharma and Health Lawyer
Novartis gets EU approval for new COPD treatment - http://ow.ly/Ias3
Advertisement
